Top Stocks To Buy Now? 3 Health Care Stocks To Know

3 Trending Health Care Stocks For Your Watchlist Right Now

For investors navigating the stock market today, health care stocks would still be in fashion. Namely, the industry remains as vital to the general population as ever. Throughout the current pandemic, many names in the space have and continue to make massive strides in the operations. This would be the case from vaccine companies like Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) to retail pharmacy names like CVS Health (NYSE: CVS).

On one hand, the leading names in the coronavirus vaccine race are reported looking to expand the possible applications of their vaccine. Namely, Pfizer and BioNTech are reportedly on track to apply for FDA approval for their vaccine to be used in children 5 and older. Through an interview with the New York Times last week, Dr. Ozlem Tureci, co-founder of BioNTech, revealed the details. According to Dr. Tureci, results from trials involving children 5 to 11 years old will be released in a matter of weeks. On the other hand, CVS opened its first MinuteClinic locations in Washington. These walk-in medical clinics inside CVS Pharmacy stores provide a wide array of health care services.

On top of all this, President Joe Biden’s recent workplace vaccine mandates would continue to highlight the industry. In detail, the Department of Labor is planning to declare an emergency rule targeting all employers with over 100 employees. Said employers will have to ensure that all workers are fully vaccinated or tested at least once a week. With all that said, could one of these top health care stocks be worth your attention this week?

Top Health Care Stocks To Buy [Or Sell] This WeekModerna Inc.

To begin, we have Moderna, a biotech company that utilizes messenger RNA (mRNA) science to treat a broad spectrum of diseases across six modalities. A modality is a family of potential mRNA medicines that are consistent in both design and how and where they are delivered in the body. This would include cancer vaccines and prophylactic vaccines. The company is on track to deliver up to 1 billion doses of its coronavirus vaccine in this financial year.

With that being said, MRNA stock currently trades at $435.37 as of 10:56 a.m. ET and has increased by over 570% in the past year alone. Last week, it announced that National Resilience is seeking to build a manufacturing ecosystem to manufacture mRNA for Moderna’s coronavirus vaccine. Under the terms of the multi-year agreement, Resilience will produce mRNA at its facility in Ontario, Canada to manufacture Moderna’s vaccine for distribution worldwide.

It seems to be a busy month for the company as it also submitted data to the European Medicines Agency (EMA) for its coronavirus vaccine booster on September 3, 2021. This submission will be for conditional marketing approval (CMA) with the EMA. “We are pleased to submit for a conditional marketing approval with the EMA for our booster candidate at the 50 µg dose level. The amended Phase 2 study and additional analyses shows that a 50 µg booster dose of our COVID-19 vaccine induces robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We remain committed to staying ahead of the virus and following the evolving epidemiology of SARS-CoV-2.” Given this piece of news, will you consider buying MRNA stock?

MRNA stock chartSource: TD Ameritrade TOS

Read More

Clover Health Investments Corp.

Next up, we have Clover Health, a health care company that operates as a next-generation Medicare Advantage insurer. In essence, the company leverages its flagship software platform, the Clover Assistant to provide seniors with highly affordable health care plans. It also allows physicians to make data-driven decisions with personalized insights to improve outcomes. CLOV stock currently trades at $8.44 as of 10:56 a.m. ET.

On September 8, 2021, the company announced a partnership with athenahealth through the company’s Marketplace program. Furthermore, as part of the athenahealth Marketplace, the Clover Assistant application will be available to Clover-contracted physicians in athenahealth’s growing network of healthcare providers to offer them clinical decision support, without requiring a transition to risk-based contracts. This seamless access to innovative models of data-driven care could benefit the company in the long run.

Last month, it also reported impressive financials. Notably, its total revenue for the quarter increased by 140% year-over-year to $412 million. The company also says that lives under the Clover Management nearly doubled from the first quarter to approximately 129,000. Also, the company is on track to managing over $1 billion of annualized revenue. For these reasons, will you be adding CLOV stock to your portfolio?

CLOV stock chartSource: TD Ameritrade TOS

[Read More] Top Reddit Stocks To Buy Right Now? 5 For Your Late 2021 Watchlist

Tilray Inc.

Tilray is the last on our list today. Sure, most may not immediately think of TLRY stock when considering the top health care stocks in the stock market. However, the case for medical marijuana users across the globe continues to build regardless. With Tilray being one of the largest cannabis companies globally in terms of revenue, it is no newcomer to the medical weed market. For a sense of scale, Tilray’s operations span across the U.S., Canada, Europe, Australia, and Latin America.

Now, TLRY stock trades at $12.06 as of 10:57 a.m. ET. This would be after gaining by 120% in the past year. With both rising consumer demand and legislative momentum behind the U.S. industry now, TLRY stock could be worth watching. If anything, the company does not appear to be slowing down anytime soon. As of last week, Tilray received stockholder approval to increase its authorized shares.

According to CEO Irwin Simon, this move will serve to help Tilray further build on its strong momentum so far. Since its merger with fellow marijuana industry giant Aphria back in May, the company has made numerous significant plays. This includes the launch of a new medical brand in Canada and acquiring a majority stake in MedMen Enterprises. The latter of which would provide Tilray with a quick entry into the U.S. market should federal legalization take hold. Given all of this, would you consider TLRY stock a buy now?

TLRY stockSource: TD Ameritrade TOS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.